ELOB — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15110355	0.83	15/20
SCHEMBL15112002	0.83	15/20
SCHEMBL15110402	0.79	14/20
SCHEMBL15110438	0.75	14/20
SCHEMBL15110445	0.75	14/20
SCHEMBL15110331	0.57	13/20
SCHEMBL15110221	0.56	13/20
SCHEMBL15110257	0.80	12/20
SCHEMBL15110329	0.79	12/20
SCHEMBL15112608	0.79	12/20
SCHEMBL15110281	0.74	12/20
SCHEMBL15112677	0.70	12/20
SCHEMBL15125829	0.70	12/20
SCHEMBL15112661	0.65	12/20
SCHEMBL15110112	0.64	12/20
SCHEMBL15110424	0.61	12/20
SCHEMBL15110391	0.60	12/20
SCHEMBL15110317	0.54	12/20
SCHEMBL15110166	0.49	12/20
SCHEMBL15110047	0.47	12/20

Clinical trials — most relevant to ELOB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Valproate and Levocarnitine in Children With Spinal Muscular Atrophy	PHASE3	UNKNOWN
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders.	PHASE1/PHASE2	RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Esophageal String Test in Eosinophilic Esophagitis	nan	ACTIVE_NOT_RECRUITING
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Impact of Elastin Mediated Vascular Stiffness on End Organs	nan	COMPLETED
Research on the Early and Prognosis Diagnosis of Vascular Dementia	nan	RECRUITING
Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Novel Biophotonics Methodology for Colon Cancer Screening	nan	COMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
MEHMO Natural History and Biomarkers	nan	RECRUITING
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Molecular Profile of the Evolution of Inclusion Body Myositis	nan	COMPLETED
Genetic and Blood Biomarkers in Neurological and Neuromuscular Diseases	nan	COMPLETED
Phenotypic and Genotypic Characterization of Subjects With Syndromic Obesity: Identifying New Candidate Genes by Exome Sequencing (OBEXOME)	nan	COMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ELOB binder may also engage these)

Protein	Name	Similarity
P62870	—	1.000	P62870 →
P62869	—	0.999	P62869 →
A0A0E0SC50	—	0.970	A0A0E0SC50 →
Q9FFI2	—	0.969	Q9FFI2 →
Q4V8W7	—	0.968	Q4V8W7 →
C1BXU5	—	0.968	C1BXU5 →
Q5TZF3	—	0.967	Q5TZF3 →
Q91WS7	—	0.966	Q91WS7 →
C1BHN7	—	0.965	C1BHN7 →
Q5R8B7	—	0.965	Q5R8B7 →
Q8C0M0	—	0.965	Q8C0M0 →
Q5R8M5	—	0.965	Q5R8M5 →
Q3ZBQ1	—	0.964	Q3ZBQ1 →
C3KHF2	—	0.964	C3KHF2 →
B1AY13	—	0.963	B1AY13 →
Q94JZ8	—	0.963	Q94JZ8 →
SMCHD1	Structural maintenance of chromosomes flexible hinge domain-containing protein 1	0.963	landscape →
A4D9P4	—	0.963	A4D9P4 →
TBCB	Tubulin-folding cofactor B	0.963	landscape →
Q8VDY4	—	0.963	Q8VDY4 →
Q3V3E1	—	0.963	Q3V3E1 →
Q07139	—	0.963	Q07139 →
Q7Z494	—	0.962	Q7Z494 →
B0F9L4	—	0.962	B0F9L4 →
A2X052	—	0.962	A2X052 →
USP24	Ubiquitin carboxyl-terminal hydrolase 24	0.962	landscape →
Q8WSR4	—	0.962	Q8WSR4 →
Q500Z7	—	0.962	Q500Z7 →
Q91WB7	—	0.961	Q91WB7 →
Q8C0L9	—	0.961	Q8C0L9 →